Table 5.
Poisson regression analysis for hyposalivation, measured by unstimulated whole salivary flow rates in childhood cancer survivors (n = 257).
| Variable | Number of Survivors a | Hyposalivation < 0.2 mL/min (n) | Risk Ratio | 95% CI | p |
|---|---|---|---|---|---|
| Gender | |||||
| Male | 141 | 37 | 1.0 (ref) | ||
| Female | 116 | 46 | 1.52 | 1.06 to 2.19 | 0.023 |
| Age at diagnosis (per 1 year increase) | 257 | 83 | 1.01 | 0.97 to 1.04 | 0.805 |
| Time since diagnosis (per 10 year increase) | 257 | 83 | 1.42 | 1.15 to 1.75 | 0.001 |
| Radiotherapy dose (Gy) to salivary glands | |||||
| 0 Gy b | 184 | 49 | 1.0 (ref) | ||
| >0 and ≤12 Gy | 26 | 10 | 1.48 | 0.89 to 2.47 | 0.128 |
| >12 and ≤34 Gy | 32 | 16 | 1.31 | 0.83 to 2.07 | 0.240 |
| >34 Gy | 15 | 8 | 2.10 | 1.21 to 3.63 | 0.008 |
| Number of medications (per 1 number increase) | 257 | 83 | 1.02 | 0.94 to 1.11 | 0.621 |
Gy: gray, (ref): reference category. a 12 participants were excluded from this analysis due to unclear information about: radiotherapy (n = 1), radiotherapy to salivary glands (n = 6) and the number of medication (n = 5). b Group of RT dose of 0 Gray consists of Group 1: chemotherapy (n = 178) and survivors who did receive H&N RT but not to salivary glands (n = 6).